Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

NCT03297398 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

114

Enrollment

INDUSTRY

Sponsor class

Stopped study terminated by sponsor decision

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: Group-1 (15mg, OPK-88004)
DRUG: Group-2 (25 mg,OPK-88004)
OTHER: Placebo

Sponsor

OPKO Health, Inc.